In an interview with School of Medicine Dean Dr. Mary Klotman, Dr. David Ashley explains some of the challenges of treating brain tumors and the exciting advancements his team is pursuing, including the recent FDA approval of a drug for low-grade gliomas. Ashley, director of the brain tumor center, outlines the team's interdisciplinary approach to developing the treatment and administering it here at Duke.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
